Early results encourage Pluristem as it advances mesenchymal cell therapies
This article was originally published in Scrip
Buoyed by outcomes described by one patient's doctor as a "medical miracle," Pluristem Therapeutics is carefully weighing its options for the specific bone marrow-related indication it will pursue for its PLX (PLacental eXpanded) cell therapy - mesenchymal cells harvested from allogeneic (donor-derived) placental tissue that are attached to therapeutic proteins to induce an immune response.
You may also be interested in...
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.